Klasse News!! deutl. Discout in Deutschland! - 500 Beiträge pro Seite

[tdwzb]

Targeted Genetics - TGEN (Nasdaq) - 896 323

akt.: 1,25€ - ABER: USA 1,90$ (= 1,42€)


Press Release Source: Celladon Corporation; Targeted Genetics Corporation


Celladon and Targeted Genetics Announce a Collaboration to Develop AAV-Based Gene Therapies for Congestive Heart Failure
Tuesday January 4, 8:49 am ET
- [rred]Deal Terms Include $6 Million Equity Investment in Targeted Genetics by Celladon`s Lead Investors[/red] -


SEATTLE and LA JOLLA, Calif., Jan. 4 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN - News) and Celladon Corporation today announced a collaboration agreement to develop adeno associated virus (AAV)-based gene therapies for the treatment of congestive heart failure. Simultaneous with the initiation of this collaboration, Enterprise Partners and Venrock Associates, venture capital funds that have invested in Celladon, made a $6 million common stock investment in Targeted Genetics.
The collaboration combines Targeted Genetics` expertise in the development, manufacture and clinical evaluation of AAV-based therapies with Celladon`s portfolio of genes with potential in the treatment of congestive heart failure. Under the terms of the agreement, Targeted Genetics and Celladon will work together to develop AAV vectors for the treatment of heart failure.

"Celladon was founded with the goal of becoming the leader in developing molecular therapies for congestive heart failure," said Drew Senyei, M.D., Chairman at Celladon and Managing Director at Enterprise Partners Venture Capital. "An extensive evaluation of available gene delivery technologies has led us to believe that AAV vectors have the greatest potential to address the medical and commercial needs of a chronic disease such as congestive heart failure. We believe that Targeted Genetics is the partner of choice for developing AAV-based products due to their exceptional expertise in the development, manufacture and clinical evaluation of gene based therapies."

"Our collaboration with Celladon broadens our leadership position and development of AAV-based therapies and presents an exciting opportunity to expand our capabilities into the area of congestive heart failure," said H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics. "The ability of AAV vectors to deliver genes to cardiac muscle cells combined with the long-term gene expression properties of these vectors makes them particularly exciting in the treatment of chronic cardiac diseases such as congestive heart failure. Five million people in the United States today are living with congestive heart failure, and our efforts to innovate new therapies in this area are consistent with our mission to address diseases with significant unmet medical need."

"Celladon`s therapeutic candidates target the SERCA2a pathway, an important regulator of myocardial contractility. Malfunction in this pathway can lead to progressive heart failure," said Krisztina Zsebo, President of Celladon Corporation. "Pre-clinical studies by Celladon`s co-founders, Dr. Kenneth R. Chien M.D., Ph.D. and Dr. Roger J. Hajjar, M.D., prominent researchers in the field of cardiovascular medicine, indicate that AAV agents targeting this pathway can reverse the progression of congestive heart failure in animal models. Gene delivery may provide a new approach to unlocking the therapeutic potential of this pathway, whereas previous traditional small molecule attempts have not been successful."

Under the terms of the collaboration agreement, Targeted Genetics agreed to commit $2 million towards the development, manufacture and preclinical development of AAV vectors containing the SERCA2a gene and phospholamban gene mutations. Celladon agreed to cover all additional development, manufacture and preclinical development costs. Targeted Genetics will receive milestone payments upon the completion of pre-specified product development milestones, and also will receive significant royalties on any sales of potential products commercialized under the collaboration. Simultaneously with the signing of the agreement with Celladon, Celladon investors Enterprise Partners and Venrock Associates purchased $6 million of Targeted Genetics` stock in a directed public offering at $1.52 per share.

"We are pleased that these investors have decided to increase their investment in our company beyond the amount of funding committed to the Celladon collaboration. In addition to funding development activities under the collaboration, this investment will also help to support our other therapeutic product development programs," said Todd E. Simpson, Chief Financial Officer of Targeted Genetics.

[tdwzb]

chart bricht bei 1,80/1,85$ auch vehement aus

[Waterkant]

Also Investoren haben bei USD 1.52 gekauft und vorbörslich sind die 1.64 USD Brief... No big deal...

Danke Waterkant

[tdwzb]

#3
??

pre-market aktuell 1,90$!!!
das sind 1,42€

[tdwzb]

mir gefällt der chart außerordentlich gut
ab 2$ geht´s wohl richtig los..

[Waterkant]

Sorry, mein Fehler... Die Briefseite war von gestern... handeln an der 1.90-Kante...
Technisch sehen sie dann tatsaechlich gut aus...

Waterkant

[tdwzb]

eben..
m.e. ist das eine klasse news

- neue kooperation bzgl. F&E
- liqu.zufluß (1,52$ ist fair)
- imagegewinn durch den partner
...

akt. 1,83$ = 1,37€

[abauer1050]

ARGETED GENETICS INVITES YOU TO JOIN ITS FOURTH QUARTER AND YEAR-END 2004 EARNINGS CALL ON THE WEB, 2/24/05

Seattle, WA – February 24, 2005 – Targeted Genetics Corporation (NASDAQ: TGEN) invites you to listen to its investor and analyst conference call, which will be held in conjunction with the release of the Company’s Fourth Quarter and Year End 2004 financial results. The call will be broadcast live over the Internet on Thursday, March 3, 2005, at 10:30am EST.

What: Targeted Genetics Corporation Fourth Quarter and Year End 2004 financial results

When: Thursday, March 3, 2005, 10:30am EST

Where: www.targetedgenetics.com

If you are unable to participate during the live webcast, the call will be archived for 30 days at www.targetedgenetics.com. The replay also will be available for 30 days by dialing 800-207-7077 (domestic) or 913-383-5767 (international) and using PIN #4088.

About Targeted Genetics
Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and inflammatory arthritis. The Company also has a promising pipeline of product candidates focused on hyperlipidemia, congestive heart failure and Huntington’s disease, which are being developed under collaboration agreements with others, and a broad platform of gene delivery technologies for application in nucleic acid-based drug development. For more information about Targeted Genetics, visit its website at www.targetedgenetics.com.

Contact: Stacie Byars
206-521-7392

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
NOTE: This release contains forward-looking statements regarding our product pipeline and clinical trials. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain regulatory approval and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our report on Form 10-Q for the quarter ended September 30, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.



http://www.targen.com/investor/pr-detail.php/id=197